Cargando…
The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple organs. It is often called “immortal cancer” due to the difficulties in disease treatment. As the cornerstone of immune regulation, the programmed cell death protein 1 (PD-1) has been extensively studied in the con...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030866/ https://www.ncbi.nlm.nih.gov/pubmed/36969198 http://dx.doi.org/10.3389/fimmu.2023.1111005 |